July 5th 2025
Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.
Nasal Polyps in CRS Found to Influence Risk of Past, Current Proton Pump Inhibitor Use
June 16th 2022Incidence of chronic rhinosinusitis (CRS) was associated with a higher rate of current and past proton pump inhibitor (PPI) use, in which elevated risk of PPI use and prescription duration were only found in those with CRS who did not have nasal polyps.
Read More
Dr Mazyar Shadman Highlights the Challenges of Subgroup Analysis When Trials Lack Diversity
June 16th 2022Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.
Watch
Symptom Burden, QOL in CRSwNP Significantly Improved With Novel Fluticasone Delivery System
June 14th 2022Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.
Read More
The FDA determined that the 3-dose Pfizer COVID-19 vaccine worked in children aged 6 months through 4 years; the bipartisan Senate gun deal will focuses on mental health; the pandemic has other viruses acting mysteriously, with children diagnosed with respiratory viruses in May and June.
Read More
Dr Elli Papaemmanuil Explains Novel Prognostication, Molecular Classification System for MDS
June 12th 2022Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.
Watch
John Mascarenhas, MD, director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, spoke on preliminary data findings of the phase 2 MANIFEST study investigating the efficacy and safety profile of pelabresib, ruxolitinib combination therapy in JAK inhibitor-naive patients with myelofibrosis and those with suboptimal response to ruxolitinib monotherapy.
Watch
Dr Mandy Lauw Reviews YoungEHA, AI, and Ethics in Hematology at EHA2022
June 11th 2022Mandy Lauw, MD, PhD, physician scientist and chair of the YoungEHA committee, discussed the content presented at the YoungEHA Research Meeting at the 2022 European Hematology Association (EHA) Congress and core themes of the session she cochaired on the ethics of artificial intelligence (AI) and science in hematology.
Watch
Swaminathan P. Iyer, MD, of the University of Texas MD Anderson Cancer Center, explains the mechanism of action and efficacy/safety observed in phase 1 results of CTX130, a CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy, in the treatment of relapsed/refractory T-cell lymphoma.
Watch
Dr Constantine Tam Discusses Impact of Public Funding for BTK Inhibitor Use in R/R CLL
June 10th 2022Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s pharmaceuticals benefit scheme on the rise of Bruton tyrosine kinase (BTK) inhibitor prescriptions for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as well as reasons behind the decrease in fludarabine, cyclophosphamide, and rituximab combination therapy usage for first-line CLL.
Watch
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center and University of Washington, discussed positive health-related quality of life (HRQOL) findings of the SEQUOIA trial investigating zanubrutinib vs bendamustine/rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Watch
CREATE Trial Data Add to Support of Open-Source AID Use in T1D
June 9th 2022Findings presented at the 82nd Scientific Sessions of the American Diabetes Association support the safety and efficacy of open-source automated insulin delivery (AID) systems among children and adults living with type 1 diabetes (T1D).
Read More
Ashok Subramanian on Considerations for Employers Designing Value-Based Care Frameworks
June 8th 2022Ashok Subramanian, MBA, founder and chief executive officer, Centivo, speaks on the limitations of traditional employer-based health benefit plans in the pursuit of value-based care and what employers should consider in designing these incentives on a community level.
Watch
Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count
June 8th 2022Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
Read More
What We're Reading: FTC Launches PBM Inquiry; FDA Advisers Recommend Novavax; Drug Prices Soar
June 8th 2022The Federal Trade Commission (FTC) launched an inquiry into the practices of pharmacy benefit managers; FDA advisers overwhelmingly support approval of Novavax, a new COVID-19 vaccine; drug prices soar to 20% annual inflation.
Read More
Having Someone Who Cares: Patient Perspectives of Care Management Programs
This article presents a single-organization qualitative case description of the perspectives of patients with high-need, high-cost illnesses who participated in care management programs.
Read More